PRPO (Precipio, Inc. Common Stock) Stock Analysis - News
Precipio, Inc. Common Stock (PRPO) is a publicly traded Healthcare sector company. As of May 21, 2026, PRPO trades at $24.42 with a market cap of $44.59M and a P/E ratio of -105.33. PRPO moved +0.00% today. Year to date, PRPO is +1.35%; over the trailing twelve months it is +187.46%. Its 52-week range spans $3.90 to $33.63. Rallies surfaces PRPO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in PRPO news today?
Precipio Q1 Revenue Rises 30% to $6.71M; Adjusted EBITDA Falls to -$200K: Precipio Inc generated $6.71 million in Q1 revenue, up over 30% year-over-year, with pathology services revenue rising to over $6 million. Adjusted EBITDA swung to a $200,000 loss and gross margin fell to 40% from 47% as CMS fee cuts and timing issues weighed on profitability.
Sabet Ahmed Zaki bought 19 (~$530.67) on Apr 1, 2026.
Sabet Ahmed Zaki bought 20 (~$468) on Jan 2, 2026.
Sabet Ahmed Zaki bought 20 (~$468) on Jan 2, 2026.
PRPO Analyst Consensus
PRPO analyst coverage data. Average price target: $0.00.
Common questions about PRPO
What changed in PRPO news today?
Precipio Q1 Revenue Rises 30% to $6.71M; Adjusted EBITDA Falls to -$200K: Precipio Inc generated $6.71 million in Q1 revenue, up over 30% year-over-year, with pathology services revenue rising to over $6 million. Adjusted EBITDA swung to a $200,000 loss and gross margin fell to 40% from 47% as CMS fee cuts and timing issues weighed on profitability.
Does Rallies summarize PRPO news?
Yes. Rallies summarizes PRPO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is PRPO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PRPO. It does not provide personalized investment advice.
